Evaluation of Testis as Organ at Risk in Carcinoma Rectum with Various Radiotherapy Delivery Techniques

Tejaswi Siddappa, Poornachandra; Sunkappa, Shamsundar; Desai, Vinay; Kunigal Puttaswamy, Jagannath; Ramanand, Nanda; Katke, Aradhana; Boraiah, Thejaswini

doi:10.30476/mejc.2025.104779.2207

Evaluation of Testis as Organ at Risk in Carcinoma Rectum with Various Radiotherapy Delivery Techniques

Document Type : Original Article(s)

Authors

Poornachandra Tejaswi Siddappa ¹

Shamsundar Sunkappa ²

Vinay Desai ²

Jagannath Kunigal Puttaswamy ²

Nanda Ramanand ²

Aradhana Katke ²

Thejaswini Boraiah ²

¹ Department of Radiation Oncology, Karnataka Cancer Therapy and Research Institute, Hubli, Karnataka, India

² Department of Radiation Oncology, Kidwai Memorial Institute of Oncology, Hombegowda Nagar, Bengaluru, Karnataka, India

https://doi.org/10.30476/mejc.2025.104779.2207

Abstract

Background: Due to the close approximation of testis to radiotherapy treatment field in male carcinoma rectum patients, it receives either scattered or direct radiation. The present study aimed to investigate the impact of considering testis as organ at risk with different radiotherapy techniques.
Method: This mono-centric, multi-arm, prospective, observational study was conducted with 160 male rectal cancer patients between 2019 and 2024, aged >18 years treated with neo-adjuvant radiotherapy followed by total mesorectal resection. We designed two-dimensional, three-dimensional, intensity modulated and volumetric modulated arc radiotherapy, with 40 patients in each technique. Tumor stage, length and thickness, testicular dose and volume, planned target volume and its distance from anal verge in each technique was considered, along with the assessment of testis as organ at risk. SPSS-22.0, R environment-3.2.2 and Microsoft excel were used for data analysis. The two-tailed t-test and analysis of variance (ANOVA) were performed to assess the level of significance with P < 0.05.
Results: The mean dose to right and left testis (in centi-gray) with two-dimensional radiotherapy was 925.79 and 776.70, while the dose contribution to testis when considered as organ at risk resulted in 336.23 and 206.65 with three-dimensional radiotherapy, 165.15 and 140.25 in intensity modulated radiotherapy and 209.2 and 229.2 in volumetric modulated arc therapy. Planned target volume, testis as organ at risk and treatment technique showed statistical significance with testicular dose received.
Conclusion: Considering testis as organ at risk contributed to significant dose reduction in conformal technique, with better sparing observed in intensity modulated radiotherapy whereas testicular shielding is needed in two-dimensional radiotherapy.

Keywords

Testis

Organs at risk

Neoadjuvant therapy

Radiotherapy

Rectal neoplasms

Subjects

Cancer Treatment

How to cite this article:

Siddappa PT, Sunkappa S, Desai V, Puttaswamy JK, Ramanand N, Katke A, et al. Evaluation of testis as organ at risk in carcinoma rectum with various radiotherapy delivery techniques. Middle East J Cancer. 2026; 17(2): 144-51 doi: 10.30476/mejc.2025. 104779.2207.

1. Duzova M, Basaran H, Inan G, Gul OV, Eren OO, Korez MK. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: Outcomes of survival, toxicity, sphincter preserving and prognostic factors. Transpl Immunol. 2021;69:101489. doi: 10.1016/j.trim.2021.101489. PMID: 34687908.
2. Wiltink LM, Chen TY, Nout RA, Kranenbarg EM, Fiocco M, Laurberg S, et al. Health-related quality of life 14 years after preoperative short-term radiotherapy and total mesorectal excision for rectal cancer: report of a multicenter randomised trial. Eur J Cancer. 2014;50(14):2390-8. doi: 10.1016/j.ejca.2014.06.020. PMID: 25060825.
3. Ghadimi M, Rödel C, Hofheinz R, Flebbe H, Grade M. Multimodal treatment of rectal cancer. Dtsch Arztebl Int. 2022;119(33-34):570-80. doi: 10.3238/arztebl. m2022.0254. PMID: 35791271; PMCID: PMC 9743213.
4. Luo B, Fan C, Xie X, Loftås P, Sun XF. Preoperative radiotherapy decision-tree for rectal cancer patients: A real-world analysis based on the swedish colorectal cancer registry. Clin Colorectal Cancer. 2023;22(3): 280-90. doi: 10.1016/j.clcc. 2023.04.001. PMID: 37270356.
5. Haber L, Allen A, Rune KT. Sexual quality of life following a cancer diagnosis: a qualitative study. Support Care Cancer. 2023;31(2):125. doi: 10.1007/s00520-022-07459-8. PMID: 36680658; PMCID: PMC9860240.
6. Sörensson M, Asplund D, Matthiessen P, Rosenberg J, Hallgren T, Rosander C, et al. Self-reported sexual dysfunction in patients with rectal cancer. Colorectal Dis. 2020;22(5):500-12. doi: 10.1111/codi.14907. PMID: 31713295; PMCID: PMC7317395.
7. Hansen SB, Oggesen BT, Fonnes S, Rosenberg J. Erectile dysfunction is common after rectal cancer surgery: A cohort study. Curr Oncol. 2023;30(10):9317-26. doi:10.3390/curroncol30100673. PMID: 37887573; PMCID: PMC10605730.
8. Costa P, Cardoso JM, Louro H, Dias J, Costa L, Rodrigues R, et al. Impact on sexual function of surgical treatment in rectal cancer. Int Braz J Urol. 2018;44(1):141-9. doi: 10.1590/S1677-5538.IBJU. 2017.0318. PMID: 29219281; PMCID: PMC5815544.
9. De Felice F, Marchetti C, Marampon F, Cascialli G, Muzii L, Tombolini V. Radiation effects on male fertility. Andrology. 2019;7(1):2-7. doi: 10.1111/andr.12562.PMID: 30411532.
10. Fukunaga H, Yokoya A, Prise KM. A brief overview of radiation-induced effects on spermatogenesis and oncofertility. Cancers (Basel). 2022;14(3):805. doi: 10.3390/cancers14030805. PMID: 35159072; PMCID: PMC8834293.
11. Jia SB, Soleimani A, Mirsadraee M, Zarifi S, Sanaeifar E. Evaluation of the effectiveness of testicular shielding in rectal cancer radiotherapy. Radiation Physics and Chemistry. 2023;202:110435. doi: 10.1016/j. radphyschem.2022.110435.
12. Singhal MK, Kapoor A, Singh D, Bagri PK, Narayan S, Nirban RK, et al. Scattered radiation to gonads: role of testicular shielding for para-aortic and homolateral illiac nodal radiotherapy. J Egypt Natl Canc Inst. 2014;26(2):99-101. doi: 10.1016/j.jnci. 2014.03.002. PMID: 24841161.
13. Rödel C. ASTRO Clinical Practice Statement for the appropriate customization of radiation therapy for rectal cancer: A European perspective. Pract Radiat Oncol. 2016;6(3):e49-e51. doi: 10.1016/j.prro. 2016.01.005. PMID: 26952814.
14. Wo JY, Anker CJ, Ashman JB, Bhadkamkar NA, Bradfield L, Chang DT, et al. Radiation therapy for rectal cancer: Executive summary of an ASTRO clinical practice guideline. Pract Radiat Oncol. 2021;11(1):13-25. doi: 10.1016/j.prro.2020.08.004. PMID: 33097436.
15. Wang X, Ji X. Sample size estimation in clinical research: From randomized controlled trials to observational studies. Chest. 2020 ;158(1S):S12-S20. doi: 10.1016/j.chest.2020.03.010. PMID: 32658647.
16. Gul OV, Basaran H, Inan G. Evaluation of incidental testicular dose with thermoluminescence dosimetry during prostate radiotherapy. Med Dosim. 2022;47(3):203-6. doi: 10.1016/j.meddos. 2022.02.007. PMID: 35287998.
17. Farhood B, Mortezaee K, Haghi-Aminjan H, Khanlarkhani N, Salehi E, Nashtaei MS, et al. A systematic review of radiation-induced testicular toxicities following radiotherapy for prostate cancer. J Cell Physiol. 2019;234(9):14828-37. doi: 10.1002/jcp.28283.PMID: 30740683.
18. Georgakopoulos I, Kouloulias V, Ntoumas GN, Desse D, Koukourakis I, Kougioumtzopoulou A et al. Radiotherapy and testicular function: A comprehensive review of the radiation-induced effects with an emphasis on spermatogenesis. Biomedicines. 2024;12(7):1492. doi: 10.3390/ biomedicines12071492. PMID: 39062064; PMCID: PMC11274587.
19. Sourati A, Malekzadeh M, Bakhshandeh M, Moosavizadeh A, Azma Z. Evaluation of relationship between testicular dose and hormonal changes after radiotherapy in patients with rectal cancer. Rep Radiother Oncol. 2015;2(1). doi: 10.5812/rro. 885.
20. Frøseth TC, Strickert T, Solli KS, Salvesen Ø, Frykholm G, Reidunsdatter RJ. A randomized study of the effect of patient positioning on setup reproducibility and dose distribution to organs at risk in radiotherapy of rectal cancer patients. Radiat Oncol. 2015;10:217. doi: 10.1186/s13014-015-0524-3. PMID: 26508131; PMCID: PMC4624657.
21. Yang Y, Cai S, Zhao T, Peng Q, Qian J, Tian Y. Effect of prone and supine treatment positions for postoperative treatment of rectal cancer on target dose coverage and small bowel sparing using intensity-modulated radiation therapy. Transl Cancer Res. 2020:491-9. doi: 10.21037/tcr.2019.11.33. PMID: 35117393; PMCID: PMC8799155.
22. Kim A, Karotki A, Presutti J, Gonzales G, Wong S, Chu W. The effect of prone and supine treatment positions for the pre-operative treatment of rectal cancer on organ-at-risk sparing and setup reproducibility using volumetric modulated arc therapy. Radiat Oncol. 2017;12(1):180. doi: 10.1186/s13014-017-0918-5. PMID: 29202879; PMCID: PMC57 15653.